ArticleBMC gastroenterology2026
Myeloid Mcpip1/Regnase-1 regulates intestinal homeostasis by modulating epithelial cell differentiation.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMCPIP1/Regnase-1 is a negative regulator of the inflammatory response, and its protective role against the development of various pathological conditions, including intestinal diseases, has been documented. Importantly, the biological effects of MCPIP1 are cell-specific.
methodsMyeloid-specific Zc3h12a knockout (Mcpip1MKO) mice were generated using the Cre-loxP system. Acute colitis was induced with 3% DSS, and disease severity was assessed by DAI scoring, histology, and intestinal permeability assays. Colon tissues and bone marrow-derived monocytes were analyzed via qRT-PCR, immunostaining, and confocal microscopy.
resultsIn this study, we focused on its role in submucosal macrophages, which serve as key sentinels of the intestinal immune system. Using macrophage-specific Mcpip1-deficient mice, we report that myeloid MCPIP1 controls the homeostasis of intestinal secretory cells through negative regulation of the Notch signaling pathway. The underlying molecular mechanism involves MCPIP1-dependent repression of Notch ligands in macrophages, including Jagged1, Dll3, and Dll4, which control proper differentiation of intestinal stem cells (ISCs). Depletion of MCPIP1 enhances epithelial proliferation and the number of Lgr5⁺ stem cells in colon, but fails to maintain their differentiation into secretory lineages. Moreover, in Mcpip1-deficient macrophages, activation of the Notch pathway is further enhanced in response to bacterial components and microorganisms penetrating from the gut lumen. In consequence, mucosal barrier integrity is compromised due to defective differentiation of secretory cells, leading to a significant reduction in the mucus layer and severe colitis, highlighting the physiological significance of our findings.
conclusionsOur study provides novel mechanistic insight into the role of macrophages in ISC differentiation and establish MCPIP1 as a key immune regulator of intestinal stem cell fate via macrophage-derived Notch signaling. An immune - epithelial axis that links innate immune regulation to epithelial barrier function and colitis pathogenesis, thereby opening new avenues for therapeutic intervention in intestinal inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.